Jose Montoya

Jose Montoya is an Infectious disease doctor and Professor of Medicine (Infectious Diseases and Geographic Medicine) at Stanford University Medical Center. His special areas of clinical focus include: Chronic Fatigue Syndrome, Infectious Disease, Toxoplasmosis, Infection in the setting of solid organ transplantation, and Infection as a trigger of chronic diseases.

Dr. Montoya heads the Stanford ME/CFS Initiative.

Education

 * 1994, Fellowship:Stanford University School of Medicine,California, USA
 * 1990, Residency:Tulane University School of Medicine, Louisiana, USA
 * 1988, Internship:Tulane University School of Medicine
 * 1985, Medical Education:Universidad Del Valle, Colombia

Clinical practice
Dr. Montoya and his team at the Stanford ME/CFS Initiative have short term goals of Patient Care, Research and Discovery, and Education. They, also, have a long term goal of establishing an inpatient center, apart from a hospital where patients with chronic conditions could receive long-term treatment.

At present there is a waiting list to see Dr. Montoya. If you would like to be placed on the waiting list, please contact the New Patient Coordinator at (650) 736-5200.

Clinic address
2nd Floor of Hoover Pavilion, 211 Quarry Road, Palo Alto, CA 94304. Phone: (650) 736-5200.

Awards

 * 2016, Infectious Disease Specialist Jose G. Montoya, MD, to be Recognized as a 2016 Top Doctor in Stanford, California
 * 2013, Selected as one of the 100 Colombians who have exceled abroad, 2013 Edition., 100 Colombianos en el exterior
 * 2011, Fellow of the American College of Physicians (FACP), American College of Physicians
 * 2011, Fellow of the Infectious Diseases Society of America (FIDSA), Infectious Diseases Society of America
 * 2011, The Arthur L. Bloomfield Award for Excellence in the Teaching of Clinical Medicine, Stanford University School of Medicine
 * 2003, Chief Residents Teaching Award for exemplary teaching at Stanford Resident's report, Department of Medicine, Stanford University School of Medicine
 * 2002, The Kenneth Vosti Teaching Award for Excellence in Teaching, Division of Infectious Diseases, Department of Medicine, Stanford University School of Medicine
 * 2001, The David A. Rytand Teaching Award for Excellence in Clinical Teaching., Department of Medicine, Stanford University School of Medicine
 * 2000, The Kenneth Vosti Teaching Award for Excellence in Teaching, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine
 * 1998, The David A. Rytand Teaching Award for Excellence in Clinical Teaching, Department of Medicine, Stanford University School of Medicine
 * 1997, The Arthur L. Bloomfield Award for Excellence in the Teaching of Clinical Medicine, Stanford University School of Medicine
 * 1995, The Henry J. Kaiser Award for Excellence in Clinical Teaching, Stanford University School of Medicine
 * 1995, The Franklin G. Ebaugh, Jr. Award for Advising Medical Students, Stanford University School of Medicine
 * 1990, Outstanding Senior Resident Awar, Department of Medicine, Tulane University School of Medicine
 * 1990, The Department of Medicine Outstanding Teaching Award, Tulane University School of Medicine
 * 1990, The Owl Club Award for Outstanding Clinical Teaching, Tulane University School of Medicine
 * 1988, Outstanding Intern Award, Department of Medicine, Tulane University School of Medicine

Notable Studies

 * 2015, Right Arcuate Fasciculus Abnormality in Chronic Fatigue Syndrome"'Abstract - Methods: Fifteen patients with CFS were identified by means of retrospective review with an institutional review board–approved waiver of consent and waiver of authorization. Fourteen age- and sex-matched control subjects provided informed consent in accordance with the institutional review board and HIPAA...Results: In the CFS population, FA was increased in the right arcuate fasciculus (P = .0015), and in right-handers, FA was also increased in the right inferior longitudinal fasciculus (ILF) (P = .0008). In patients with CFS, right anterior arcuate FA increased with disease severity (r = 0.649, P = .026). Bilateral white matter volumes were reduced in CFS (mean ± standard deviation, 467 581 mm3 ± 47 610 for patients vs 504 864 mm3 ± 68 126 for control subjects, P = .0026), and cortical thickness increased in both right arcuate end points, the middle temporal (T = 4.25) and precentral (T = 6.47) gyri, and one right ILF end point, the occipital lobe (T = 5.36). ASL showed no significant differences...Conclusions: Bilateral white matter atrophy is present in CFS. No differences in perfusion were noted. Right hemispheric increased FA may reflect degeneration of crossing fibers or strengthening of short-range fibers. Right anterior arcuate FA may serve as a biomarker for CFS.'"
 * 2015, Distinct plasma immune signatures in ME/CFS are present early in the course of illness FULL TEXT"'Abstract: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is an unexplained incapacitating illness that may affect up to 4 million people in the United States alone. There are no validated laboratory tests for diagnosis or management despite global efforts to find biomarkers of disease. We considered the possibility that inability to identify such biomarkers reflected variations in diagnostic criteria and laboratory methods as well as the timing of sample collection during the course of the illness. Accordingly, we leveraged two large, multicenter cohort studies of ME/CFS to assess the relationship of immune signatures with diagnosis, illness duration, and other clinical variables. Controls were frequency-matched on key variables known to affect immune status, including season of sampling and geographic site, in addition to age and sex. We report here distinct alterations in plasma immune signatures early in the course of ME/CFS (n = 52) relative to healthy controls (n = 348) that are not present in subjects with longer duration of illness (n = 246). Analyses based on disease duration revealed that early ME/CFS cases had a prominent activation of both pro- and anti-inflammatory cytokines as well as dissociation of intercytokine regulatory networks. We found a stronger correlation of cytokine alterations with illness duration than with measures of illness severity, suggesting that the immunopathology of ME/CFS is not static. These findings have critical implications for discovery of interventional strategies and early diagnosis of ME/CFS.'"
 * 2013, Daily cytokine fluctuations, driven by leptin, are associated with fatigue severity in chronic fatigue syndrome: evidence of inflammatory pathology"'Abstract - Methods: Ten women meeting the Fukuda diagnostic criteria for CFS and ten healthy age- and body mass index (BMI)-matched women underwent 25 consecutive days of blood draws and self-reporting of symptom severity. A 51-plex cytokine panel via Luminex was performed for each of the 500 serum samples collected. Our primary hypothesis was that daily fatigue severity would be significantly correlated with the inflammatory adipokine leptin, in the women with CFS and not in the healthy control women. As a post-hoc analysis, a machine learning algorithm using all 51 cytokines was implemented to determine whether immune factors could distinguish high from low fatigue days. Results: Self-reported fatigue severity was significantly correlated with leptin levels in six of the participants with CFS and one healthy control, supporting our primary hypothesis. The machine learning algorithm distinguished high from low fatigue days in the CFS group with 78.3% accuracy. Conclusions: Our results support the role of cytokines in the pathophysiology of CFS."
 * 2013, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Valganciclovir in a Subset of Patients With Chronic Fatigue Syndrome"'Abstract: There is no known treatment for chronic fatigue syndrome (CFS). Little is known about its pathogenesis. Human herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV) have been proposed as infectious triggers. Thirty CFS patients with elevated IgG antibody titers against HHV-6 and EBV were randomized 2:1 to receive valganciclovir (VGCV) or placebo for 6 months in a double-blind, placebo-controlled trial. Clinical endpoints aimed at measuring physical and mental fatigue included the Multidimensional Fatigue Inventory (MFI-20) and Fatigue Severity Scale (FSS) scores, self-reported cognitive function, and physician-determined responder status. Biological endpoints included monocyte and neutrophil counts and cytokine levels. VGCV patients experienced a greater improvement by MFI-20 at 9 months from baseline compared to placebo patients but this difference was not statistically significant. However, statistically significant differences in trajectories between groups were observed in MFI-20 mental fatigue subscore (P = 0.039), FSS score (P = 0.006), and cognitive function (P = 0.025). VGCV patients experienced these improvements within the first 3 months and maintained that benefit over the remaining 9 months. Patients in the VGCV arm were 7.4 times more likely to be classified as responders (P = 0.029). In the VGCV arm, monocyte counts decreased (P < 0.001), neutrophil counts increased (P = 0.037) and cytokines were more likely to evolve towards a Th1-profile (P < 0.001). Viral IgG antibody titers did not differ between arms. VGCV may have clinical benefit in a subset of CFS patients independent of placebo effect, possibly mediated by immunomodulation and/or antiviral effect. Further investigation with longer treatment duration and a larger sample size is warranted.'"
 * 2012, Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers."'Abstract: Valganciclovir has been reported to improve physical and cognitive symptoms in patients with chronic fatigue syndrome (CFS) with elevated human herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV) IgG antibody titers. This study investigated whether antibody titers against HHV-6 and EBV were associated with clinical response to valganciclovir in a subset of CFS patients. An uncontrolled, unblinded retrospective chart review was performed on 61 CFS patients treated with 900 mg valganciclovir daily (55 of whom took an induction dose of 1,800 mg daily for the first 3 weeks). Antibody titers were considered high if HHV-6 IgG ? 1:320, EBV viral capsid antigen (VCA) IgG ? 1:640, and EBV early antigen (EA) IgG ? 1:160. Patients self-rated physical and cognitive functioning as a percentage of their functioning prior to illness. Patients were categorized as responders if they experienced at least 30% improvement in physical and/or cognitive functioning. Thirty-two patients (52%) were categorized as responders. Among these, 19 patients (59%) responded physically and 26 patients (81%) responded cognitively. Baseline antibody titers showed no significant association with response. After treatment, the average change in physical and cognitive functioning levels for all patients was +19% and +23%, respectively (P < 0.0001). Longer treatment was associated with improved response (P = 0.0002). No significant difference was found between responders and non-responders among other variables analyzed. Valganciclovir treatment, independent of the baseline antibody titers, was associated with self-rated improvement in physical and cognitive functioning for CFS patients who had positive HHV-6 and/or EBV serologies. Longer valganciclovir treatment correlated with an improved response.'"

Talks & Interviews

 * 2016, 12th International IACFS/ME Biennial Clinical and Research Conference, Emerging Science and Clinical Care, Paper presentations:Exercise testing highlights differences in cytokine profile and network between patients with chronic fatigue syndrome and healthy sedentary participants and A profile of circulating cytokines is associated with disease severity in chronic fatigue syndrome patients
 * 26 July 2016, Stanford leads fight against chronic fatigue by ABC7News
 * Aug 2014, [[ME/CFS Alert] Episode 65: Dr. Jose Montoya Interviewed by Deborah Waroff]
 * Mar 2011, Stanford's Dr. Jose Montoya on Chronic Fatigue Syndrome

Notable quotes
Back in 2005, while attending a conference on toxoplasmosis in Paris, Montoya told his mentor that he wanted to research ME/CFS. His mentor scoffed at the idea, pointing to a homeless person lying in a Parisian gutter. 'That’s going to be you if you go into chronic fatigue research,' the mentor told him.

Online presence

 * Jose G. Montoya Stanford Medicine Profile
 * Stanford ME/CFS Initiative

Learn more

 * 2016, Stanford lead fight against chronic fatigue syndrome
 * 2016, Will 2016 Finally be Montoya's Year? Taking Stock of the Stanford ME/CFS Initiative
 * 2014, Brains of People With Chronic Fatigue Syndrome Offer Clues About Disorder